News

Learn how and why East Indian Sandalwood Oil (EISO) is making international headlines as a unique, non-substitutable botanical drug candidate.

Santalis Pharmaceuticals Enrolls First U.S. Subject Into a Phase 2 Clinical Study of Mild to Moderate Atopic Dermatitis

Posted on

SAN ANTONIO – (MEDIA) – Santalis Pharmaceuticals has announced enrollment of the first U.S. subject into a multi-center, placebo-controlled, double-blind, safety, tolerability and efficacy study of a unique 5% Sandalwood Album Oil (SAO), also known as East Indian Sandalwood Oil (EISO), cream formulation for the treatment of atopic dermatitis (AD), also known as eczema. Subjects will be 18 to 65 […]Read More Santalis Pharmaceuticals Enrolls First U.S. Subject Into a Phase 2 Clinical Study of Mild to Moderate Atopic Dermatitis